12 Month Price Forecast For CYRX
Distance to CYRX Price Forecasts
CYRX Price Momentum
🤔 Considering CryoPort (CYRX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 5:34 AM UTC
CYRX Analyst Ratings & Price Targets
Based on our analysis of 15 Wall Street analysts, CYRX has a consensus that is neutral. The median price target is $11.00, with forecasts ranging from $8.00 to $15.00. Currently, there are 5 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
With CYRX currently trading at $8.57, the median price forecast suggests a 28.4% upside. The most optimistic forecast comes from Richard Baldry at Roth MKM, projecting a 75.0% upside, while Matthew Stanton at Jefferies provides the most conservative target, suggesting a -6.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CYRX Analyst Consensus
CYRX Price Target Range
Latest CYRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CYRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 17, 2025 | Needham | David Saxon | Buy | Reiterates | $11.00 |
| Nov 8, 2024 | Roth MKM | Richard Baldry | Buy | Maintains | $15.00 |
| Oct 18, 2024 | UBS | Dan Leonard | Neutral | Maintains | $9.00 |
| Aug 7, 2024 | Jefferies | Matthew Stanton | Hold | Downgrade | $8.00 |
| Aug 7, 2024 | Needham | David Saxon | Buy | Maintains | $11.00 |
| Aug 7, 2024 | UBS | Dan Leonard | Neutral | Maintains | $7.00 |
| Jul 31, 2024 | B. Riley Securities | Yuan Zhi | Buy | Upgrade | $15.00 |
| May 8, 2024 | Needham | David Saxon | Buy | Reiterates | $18.00 |
| May 3, 2024 | B. Riley Securities | Yuan Zhi | Neutral | Downgrade | $19.00 |
| Apr 4, 2024 | Jefferies | Matthew Stanton | Buy | Assumes | $21.00 |
| Mar 15, 2024 | UBS | John Sourbeer | Neutral | Maintains | $17.00 |
| Mar 13, 2024 | Stephens & Co. | Jacob Johnson | Equal-Weight | Reiterates | $17.00 |
| Mar 13, 2024 | Needham | David Saxon | Buy | Maintains | $18.00 |
| Jan 18, 2024 | Needham | David Saxon | Buy | Maintains | $19.00 |
| Aug 17, 2023 | Morgan Stanley | Tejas Savant | Equal-Weight | Initiates | $16.00 |
| Aug 10, 2023 | Needham | David Saxon | Buy | Maintains | $21.00 |
| Jul 18, 2023 | UBS | John Sourbeer | Neutral | Downgrade | $17.00 |
| Jul 17, 2023 | Keybanc | Paul Knight | Sector Weight | Downgrade | $0.00 |
| Jul 17, 2023 | Stephens & Co. | Jacob Johnson | Equal-Weight | Downgrade | $15.00 |
| Jul 13, 2023 | SVB Leerink | Puneet Souda | Market Perform | Downgrade | $10.00 |
Stocks Similar to CryoPort Inc
The following stocks are similar to CryoPort based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CryoPort Inc (CYRX) Financial Data
CryoPort Inc has a market capitalization of $403.35M with a P/E ratio of -3.9x. The company generates $226.11M in trailing twelve-month revenue with a -70.1% profit margin.
Revenue growth is +0.9% quarter-over-quarter, while maintaining an operating margin of -26.9% and return on equity of -33.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
CryoPort Inc (CYRX) Company Overview
About CryoPort Inc
Provides temperature-controlled supply chain solutions.
The company operates by offering a range of temperature-controlled shipping and storage solutions tailored for the biopharma, animal health, and human reproductive medicine sectors. It generates revenue through sales of its Cryoport Express Shippers, consulting services, and various bioservices, including controlled temperature storage and logistics solutions.
Founded in 1999 and headquartered in Brentwood, Tennessee, Cryoport, Inc. serves markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Its diverse service offerings include advanced cryogenic systems and logistical support, addressing the critical needs of clients in managing biological materials and ensuring compliance with stringent regulatory standards.
Company Information
Sector
Industrials
Industry
Integrated Freight & Logistics
Employees
1,100
CEO
Mr. Jerrell W. Shelton
Country
United States
IPO Year
2005
Website
www.cryoportinc.comCryoPort Inc (CYRX) Latest News & Analysis
Cryoport, Inc. (NASDAQ: CYRX) launched its new Cryoport Express® Cryogenic HV3 Shipping System, enhancing patient accessibility and showcased it at Phacilitate's Advanced Therapies Week in Dallas.
Cryoport's new HV3 shipping system enhances patient accessibility and strengthens its market position, potentially driving revenue growth and investor confidence.
Cryoport's CRYOGENE will supply Moffitt Cancer Center with advanced biorepository services, enhancing their capabilities in Tampa and Nashville.
Cryoport's partnership with Moffitt enhances its biorepository capabilities, potentially driving revenue growth and market positioning in the biopharma sector, attracting investor interest.
Cryoport, Inc. (NASDAQ: CYRX) announced that its subsidiary MVE Biological Solutions has registered all three manufacturing facilities with the FDA, enhancing product compliance and market access.
FDA registration enhances MVE's credibility and marketability, potentially increasing sales and attracting investment, positively impacting Cryoport's stock performance.
Cryoport Remains A Disappointing Prospect
1 month agoCryoport shows slight revenue growth in Q3 2024 but remains unprofitable with cash flow challenges. Despite narrowing net losses, the overall financial outlook is negative.
Cryoport's ongoing cash flow issues and unprofitability, despite minimal revenue growth, signal potential risks for investors, as the company's share price has significantly declined.
Cryoport Expands IntegriCell™ Cryopreservation Services Solution with Opening of New Center of Excellence in Europe
2 months agoCryoport, Inc. has opened a new IntegriCell™ facility in Belgium dedicated to cryopreservation of leukapheresis materials to support cell-based therapy programs.
The opening of Cryoport's IntegriCell™ facility enhances its capacity in the growing cell-based therapy market, potentially boosting revenue and market share, which can positively impact stock performance.
Cryoport, Inc. (NASDAQ:CYRX) will hold its Q3 2024 Earnings Conference Call on November 7, 2024, at 5:00 PM ET, featuring key company executives and financial analysts.
The earnings call provides insights into Cryoport's financial performance and strategic direction, influencing investor sentiment and stock valuation based on growth potential and market positioning.
Frequently Asked Questions About CYRX Stock
What is CryoPort Inc's (CYRX) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, CryoPort Inc (CYRX) has a median price target of $11.00. The highest price target is $15.00 and the lowest is $8.00.
Is CYRX stock a good investment in 2025?
According to current analyst ratings, CYRX has 5 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.57. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CYRX stock?
Wall Street analysts predict CYRX stock could reach $11.00 in the next 12 months. This represents a 28.4% increase from the current price of $8.57. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CryoPort Inc's business model?
The company operates by offering a range of temperature-controlled shipping and storage solutions tailored for the biopharma, animal health, and human reproductive medicine sectors. It generates revenue through sales of its Cryoport Express Shippers, consulting services, and various bioservices, including controlled temperature storage and logistics solutions.
What is the highest forecasted price for CYRX CryoPort Inc?
The highest price target for CYRX is $15.00 from Richard Baldry at Roth MKM, which represents a 75.0% increase from the current price of $8.57.
What is the lowest forecasted price for CYRX CryoPort Inc?
The lowest price target for CYRX is $8.00 from Matthew Stanton at Jefferies, which represents a -6.7% decrease from the current price of $8.57.
What is the overall CYRX consensus from analysts for CryoPort Inc?
The overall analyst consensus for CYRX is neutral. Out of 15 Wall Street analysts, 5 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are CYRX stock price projections?
Stock price projections, including those for CryoPort Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
